Moderna Looks To Catch Up In COVID-19 For Kids, While Still Branching Out In Other Areas
Biotech Teases Non-COVID Respiratory Programs
The company hopes to expand Spikevax’s reach beyond the current approved population while also looking to take the lead in mRNA vaccines in other diseases.
You may also be interested in...
Xevudy, which was part of the deal, has already seen restrictions on its use due to diminished efficacy against Omicron. Plus, Ocugen is back in the game as the FDA has released the clinical hold on its Phase II/III vaccine trial, while Pfizer/BioNTech release new booster shot data for Comirnaty in children aged 6 months-5 years.
The company announced early data for a combination vaccine against SARS-CoV-2 and influenza, which could provide a revenue opportunity of $2bn.
Most children 5-11 in the US have not yet received a single vaccination, according to CDC.